Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The breast cancer susceptibility FGFR2 provides an alternate mode of HER2 activation

Oncogene (2015)Cite this article

Subjects

Abstract

Fibroblast growth factor receptor 2 (FGFR2) has been shown reproducibly in genome-wide association studies to be associated with increased breast cancer risk. Here we show that mouse mammary tumor virus-neu mice develop breast carcinomas with FGFR2 immunoreactivity that parallels HER2 expression. FGFR2 signaling promotes HER2 shedding through the metalloprotease ADAM10 leading to intracellular accumulation of the truncated p95HER2 protein. This is accompanied by enhanced HER2 signaling and diminished sensitivity to trastuzumab. Functionally, FGFR2 facilitates HER2-mediated cell proliferation, acinar growth in three-dimensional morphogenesis assays and promotes tumor progression in mouse xenografts. These data implicate FGFR2 in a novel mechanism of ErbB activation and demonstrate an important interaction between FGFR2 and HER2 in promoting breast cancer progression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Thisse B, Thisse C, Weston JA . Novel FGF receptor (Z-FGFR4) is dynamically expressed in mesoderm and neurectoderm during early zebrafish embryogenesis. Dev Dyn 1995; 203: 377–391.

    Article  CAS  Google Scholar 

  2. Thisse B, Thisse C . Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev Biol 2005; 287: 390–402.

    Article  CAS  Google Scholar 

  3. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087–1093.

    Article  CAS  Google Scholar 

  4. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007; 39: 870–874.

    Article  CAS  Google Scholar 

  5. Tenhagen M, van Diest PJ, Ivanova IA, van der Wall E, van der Groep P . Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets. Endocr Relat Cancer 2012; 19: R115–R129.

    Article  CAS  Google Scholar 

  6. Zhu X, Asa SL, Ezzat S . Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. Mol Endocrinol 2009; 23: 1397–1405.

    Article  CAS  Google Scholar 

  7. Slattery ML, John EM, Stern MC, Herrick J, Lundgreen A, Giuliano AR et al. Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study. Breast Cancer Res Treat 2013; 140: 587–601.

    Article  CAS  Google Scholar 

  8. Wei W, Liu W, Cassol CA, Zheng W, Asa SL, Ezzat S . The breast cancer susceptibility gene product fibroblast growth factor receptor 2 serves as a scaffold for regulation of NF-kappaB signaling. Mol Cell Biol 2012; 32: 4662–4673.

    Article  CAS  Google Scholar 

  9. Naimi B, Latil A, Fournier G, Mangin P, Cussenot O, Berthon P . Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate 2002; 52: 245–252.

    Article  CAS  Google Scholar 

  10. Kondo T, Zheng L, Liu W, Kurebayashi J, Asa SL, Ezzat S . Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res 2007; 67: 5461–5470.

    Article  CAS  Google Scholar 

  11. Jelovac D, Emens LA . HER2-directed therapy for metastatic breast cancer. Oncology 2013; 27: 166–175.

    PubMed  Google Scholar 

  12. Yarden Y, Sliwkowski MX . Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127–137.

    Article  CAS  Google Scholar 

  13. Herter-Sprie GS, Greulich H, Wong KK . Activating mutations in ERBB2 and their impact on diagnostics and treatment. Front Oncol 2013; 3: 86.

    Article  Google Scholar 

  14. Fantozzi A, Christofori G . Mouse models of breast cancer metastasis. Breast Cancer Res 2006; 8: 212.

    Article  Google Scholar 

  15. Muthuswamy SK, Gilman M, Brugge JS . Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 1999; 19: 6845–6857.

    Article  CAS  Google Scholar 

  16. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007; 99: 628–638.

    Article  CAS  Google Scholar 

  17. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006; 10: 25–38.

    Article  Google Scholar 

  18. Siegel PM, Muller WJ . Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. Proc Natl Acad Sci USA 1996; 93: 8878–8883.

    Article  CAS  Google Scholar 

  19. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005; 65: 1642–1646.

    Article  CAS  Google Scholar 

  20. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421: 756–760.

    Article  CAS  Google Scholar 

  21. Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 1998; 58: 5123–5129.

    CAS  PubMed  Google Scholar 

  22. Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, Baselga J et al. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 2006; 25: 3234–3244.

    Article  CAS  Google Scholar 

  23. Yuan CX, Lasut AL, Wynn R, Neff NT, Hollis GF, Ramaker ML et al. Purification of Her-2 extracellular domain and identification of its cleavage site. Protein Expr Purif 2003; 29: 217–222.

    Article  CAS  Google Scholar 

  24. Liu PC, Liu X, Li Y, Covington M, Wynn R, Huber R et al. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther 2006; 5: 657–664.

    Article  CAS  Google Scholar 

  25. Saez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006; 12: 424–431.

    Article  CAS  Google Scholar 

  26. Spector NL, Blackwell KL . Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27: 5838–5847.

    Article  CAS  Google Scholar 

  27. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395–402.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the UHN Pathology Research Program for technical assistance. This work was supported by the Ontario Ministry of Health and Long-Term Care (OMHLTC). The views expressed here do not necessarily reflect those of the OMHLTC.

Author information

Authors and Affiliations

  1. Department of Medicine, University Health Network, Toronto, Ontario, Canada

    W Wei & S Ezzat

  2. Princess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada

    W Wei, W Liu, S Serra, S L Asa & S Ezzat

  3. Department of Pathology, University Health Network, Toronto, Ontario, Canada

    W Liu, S Serra & S L Asa

Authors
  1. W Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Serra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S L Asa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Ezzat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Ezzat.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wei, W., Liu, W., Serra, S. et al. The breast cancer susceptibility FGFR2 provides an alternate mode of HER2 activation. Oncogene (2015). https://doi.org/10.1038/onc.2014.440

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/onc.2014.440

Search

Advanced search

Quick links